← Back to Search

Antifibrotic

Donor Site Wound, FS2 0.5 for Scar (FS2 Trial)

Phase 2
Waitlist Available
Led By Anthony Papp, MD, PhD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0-2 hours; 0-9 months
Awards & highlights

FS2 Trial Summary

This trial will study the safety and effectiveness of a new ointment for managing scars after surgery. The ointment contains an antifibrogenic compound that has shown promise in preliminary studies. There are no known safety concerns with the ointment.

Eligible Conditions
  • Scar
  • Scarring
  • Hypertrophic Scar
  • Skin Graft Scar
  • Skin Graft Complications
  • Donor Site Complication
  • Keloid

FS2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0-2 hours; 0-9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0-2 hours; 0-9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Patient and Observer Scar Assessment Scale (POSAS)
Vancouver Scar Scale (VSS)
Secondary outcome measures
Adverse Events
Clinical Chemistry Results
FS2 Pharmacokinetic blood analysis data
+11 more

FS2 Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: Skin Graft Wound, FS2 0.5Experimental Treatment1 Intervention
A moisturizing cream base containing 0.50%w/w of FS2, applied to a bisected area of the skin grafted wound site.
Group II: Skin Graft Wound, FS2 0.25Experimental Treatment1 Intervention
A moisturizing cream base containing 0.25%w/w of FS2, applied to a bisected area of the skin grafted wound site.
Group III: Donor Site Wound, FS2 0.5Experimental Treatment1 Intervention
A moisturizing cream base containing 0.50%w/w of FS2, applied to a bisected area of the donor site wound (from where the skin graft skin harvested)
Group IV: Donor Site Wound, FS2 0.25Experimental Treatment1 Intervention
A moisturizing cream base containing 0.25%w/w of FS2, applied to a bisected area of the donor site wound (from where the skin graft skin harvested).
Group V: Donor Site Wound, VehiclePlacebo Group1 Intervention
A vehicle moisturizing cream base applied to a bisected area of the donor site wound (from where the skin graft skin harvested).
Group VI: Skin Graft Wound, VehiclePlacebo Group1 Intervention
A vehicle moisturizing cream base applied to a bisected area of the skin grafted wound site.

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,418 Previous Clinical Trials
2,467,068 Total Patients Enrolled
Anthony Papp, MD, PhDPrincipal InvestigatorUniversity of British Columbia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Clinical Safety and Scar Prevention Study of a Topical Antifibrotic Compound FS2.
Anthony Papp 2019. "Clinical Safety and Scar Prevention Study of a Topical Antifibrotic Compound FS2.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04186273.
All > Scar
~9 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top